Design of a Multi-epitope mRNA Vaccine Candidate Based on Reverse Vaccinology Targeting Three Key Antigens of Trypanosoma
Background
Human African Trypanosomiasis (HAT), transmitted by the tsetse fly, is a fatal endemic disease caused by the protozoan Trypanosoma brucei, leading to central nervous system paralysis and sleep disorders. While initial infection presents as simple fever and headache, the parasite's penetration of the blood-brain barrier results in severe neurological damage. Current commercial treatments suffer from low administration convenience and risks of neurotoxicity, and no FDA-approved preventive vaccine exists.
The primary obstacle to vaccine development lies in the pathogen's unique immune evasion strategy. The Variant Surface Glycoprotein (VSG) covering the parasite surface continuously switches its antigenicity, often neutralizing the host immune system's ability to form memory against a single antigen. Traditional attenuated live vaccines or protein subunit methods have struggled to overcome this extreme antigenic variation. Consequently, alternative vaccine designs combining Reverse Vaccinology—utilizing genome and protein structural data analysis—with the messenger RNA (mRNA) platform, which allows for rapid antigen combination, have begun to gain attention.
Key Findings
The research team targeted three proteins essential for persistent infection and survival in T. brucei: VSG, the central axis of antigenic variation; Heat Shock Protein 70 (HSP70), which assists in stress response and protein folding; and the Vacuolar Transporter Chaperone (VTC) complex, responsible for membrane transport and vesicle movement. We derived optimal peptide epitopes with high immunogenicity while excluding allergenic potential and cytotoxicity, after passing through a bioinformatic screening pipeline. The selected epitope combinations cover major histocompatibility complex (MHC) alleles across global population groups, achieving 100% global population coverage.
Physicochemical evaluations showed an Aliphatic index of 71.23, ensuring structural thermal stability, and a Grand Average of Hydropathy (GRAVY) score of -0.719, indicating excellent solubility. The predicted tertiary structure of the vaccine protein recorded a TM-score of 0.65 ± 0.13 and a C-score of -0.50; following structural refinement, it demonstrated thermodynamic stability with a Ramachandran plot favored region ratio of 86.8% and a Z-score of -5.26.
The ability to activate the immune system was also demonstrated at the molecular level. Molecular docking with Toll-like receptor 2 (TLR-2) and Toll-like receptor 4 (TLR-4), key mediators of innate immune recognition, formed very low binding energies of -1013.5 kJ/mol and -1002.8 kJ/mol, respectively. Binding stability was further confirmed via Molecular Dynamics (MD) simulation, Principal Component Analysis (PCA), Dynamic Cross-Correlation Matrix (DCCM), and Molecular Mechanics Generalized Born Surface Area (MM-GBSA) calculations.
Furthermore, to maximize the translation efficiency of the mRNA molecule, codon optimization was performed for the Escherichia coli expression system. A Codon Adaptation Index (CAI) of 0.9688 and a GC content of 44.70% were secured, and the structural integrity of the transcript itself was confirmed through Minimum Free Energy (MFE) analysis. Immune simulations observed the proliferation of activated B lymphocytes and T lymphocytes, along with high Immunoglobulin M (IgM) and Immunoglobulin G (IgG) antibody titers.
Significance and Outlook
This study is significant in that it completed a blueprint for a multi-epitope vaccine designed to strike intracellular and surface membrane proteins from multiple angles, effectively turning the pathogen's complex antigenic variation against itself. In particular, by going beyond the limitations of targeting VSG alone and including the essential intracellular survival factors HSP70 and VTC, the study proposes a design that fundamentally blocks vaccine evasion pathways caused by antigenic variation. As the structural stability and immunogenic potential have been clearly identified through computer modeling, this could serve as a catalyst to shorten the research period for neglected tropical disease vaccine development.
However, as these are in-silico results based on computer calculations, the critical hurdle of actual in-vivo efficacy verification remains. Prior evaluation of delivery efficiency upon loading the designed mRNA into lipid nanoparticles (LNPs), intracellular translation expression levels, and infection protection efficacy in animal models must be conducted. Monitoring long-term immune responses in response to the potential emergence of pathogen variants is also identified as a task to be addressed in the future.
BACKGROUND: Trypanosoma brucei causes Human African Trypanosomiasis (HAT), which has a devastating impact on an individual's health. Currently, there is no FDA-approved vaccine for HAT prevention. Therefore, reverse vaccinology approaches were utilized to design an mRNA vaccine candidate. METHODS: Variant surface glycoprotein, heat shock protein 70, and vacuolar transporter chaperone complex of T. brucei were targeted to predict immunogenic, non-allergenic, and non-toxic peptides. The vaccine candidate was evaluated for population coverage, biophysical attributes, structural stability, and refinement. Molecular docking, MD simulation, and MM-GBSA analyses evaluate receptor binding and complex stability. Codon optimization and in-silico cloning were conducted in Escherichia coli (strain K12) using pET-28a(+). Immune simulations predicted humoral and cellular responses, while mRNA integrity was evaluated through MFE analysis. RESULTS: The vaccine candidate achieved 100% global population coverage. Biophysical attributes indicated aliphaticity 71.23, and GRAVY score -0.719. Predicted tertiary structure (TM-score 0.65 ± 0.13, and C-score -0.50) was refined with stable validation metrics (Ramachandran score 86.8%, and Z-score -5.26). Docking predicted significant binding with TLR-2 and TLR-4 (energy scores -1013.5 and -1002.8 kJ/mol), validated through MD simulation, PCA, DCCM, MM-GBSA analyses. Codon optimization (CAI 0.9688; GC 44.70%) indicated high expression potential, and immune simulation exhibits robust antibody and cell-mediated responses, including elevated B lymphocyte, T lymphocyte levels, and IgM, IgG titers. Finally, the structural integrity of mRNA was predicted by MFE values. CONCLUSION: This in-silico designed vaccine demonstrated strong structural stability, receptor interactions, and immunogenic potential against T. [species name missing]. brucei. Experimental validation and in-vivo studies are required to verify safety and efficacy of vaccine candidate.
This vaccine candidate presents a practical alternative to improve health security in sub-Saharan Africa, the habitat of the tsetse fly. Existing chemotherapeutic agents require long-term hospitalization and intravenous administration, making them difficult to apply in remote villages with poor medical infrastructure. If this multi-epitope mRNA vaccine is commercialized in combination with freeze-drying technology or thermostable formulations, it could become a public health weapon to block disease spread through mass vaccination. Furthermore, since it was designed with 100% population coverage in mind, its potential for wide application regardless of racial background increases the possibility of collaboration with global vaccine production companies.